COST EFFECTIVENESS STUDY OF THE RECOMBINANT COAGULATION FACTOR VIII UNITED TO PROTEIN FC FOR THE TREATMENT OF HEMOPHILIA A IN CHILE

被引：0
|
作者：
Vargas, C. [1 ]
Balmaceda, C. [1 ]
Rodriguez, F. [2 ]
Rojas, R. [1 ]
Espinoza, M. A. [3 ]
机构：
[1] Pontificia Univ Catolica Chile, Santiago, Chile
[2] Univ San Sebastian, Santiago, Chile
[3] Univ York, Ctr Econ Salud, York, N Yorkshire, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2700
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY29
引用
收藏
页码：A894 / A895
页数：2
相关论文
共 50 条
  • [31] Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
    Alvarez-Roman, Maria-Teresa
    Shapiro, Amy D.
    Ragni, Margaret V.
    Palmborg, Helena
    Bystricka, Linda
    Szamosi, Johan
    Casiano, Sandra
    Chambost, Herve
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (06)
  • [32] Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
    Powell, Jerry S.
    Pasi, K. John
    Ragni, Margaret V.
    Ozelo, Margareth C.
    Valentino, Leonard A.
    Mahlangu, Johnny N.
    Josephson, Neil C.
    Perry, David
    Manco-Johnson, Marilyn J.
    Apte, Shashikant
    Baker, Ross I.
    Chan, Godfrey C.
    Novitzky, Nicolas
    Wong, Raymond S.
    Krassova, Snejana
    Allen, Geoffrey
    Jiang, Haiyan
    Innes, Alison
    Li, Shuanglian
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Nugent, Karen
    Vigliani, Gloria
    Brennan, Aoife
    Luk, Alvin
    Pierce, Glenn F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24): : 2313 - 2323
  • [33] Recombinant factor VIII Fc fusion protein as episodic treatment for bleeding: Analysis from the A-LONG Study
    Shapiro, Amy
    Chowdary, Pratima
    Quon, Doris
    Lin, Judith
    Neelakantan, Srividya
    Jiang, Haiyan
    Dodd, Nigel
    Brennan, Aoife
    Allen, Geoff
    Pierce, Glenn F.
    [J]. HAEMOPHILIA, 2014, 20 : 16 - 16
  • [34] Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A
    Zhang, Y.
    Roberts, J.
    Tortorici, M.
    Veldman, A.
    St Ledger, K.
    Feussner, A.
    Sidhu, J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (06) : 1106 - 1114
  • [35] Dosing regimens before and following long-term treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in children with severe hemophilia A
    Nolan, Beatrice
    Liesner, Raina
    Young, Guy
    Mahlangu, Johnny
    Pasi, K. John
    Lethagen, Stefan
    Cristiano, Lynda M.
    Yuan, Huixing
    Pierce, Glenn F.
    Allen, Geoffrey
    [J]. HAEMOPHILIA, 2016, 22 : 48 - 49
  • [36] A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients
    Bukkems, Laura H.
    Heijdra, Jessica M.
    Mathias, Mary
    Collins, Peter W.
    Hay, Charles R. M.
    Tait, Robert C.
    Mangles, Sarah
    Myers, Bethan
    Evans, G.
    Bailiff, Benjamin
    Curry, Nicola
    Payne, Jeanette
    Austin, Steve
    Goedhart, Tine M. H. J.
    Leebeek, Frank W. G.
    Meijer, Karina
    Fijnvandraat, Karin
    Chowdary, Pratima
    Mathot, Ron A. A.
    Cnossen, Marjon H.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2020, 120 (05) : 747 - 757
  • [37] Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
    Mancuso, Maria Elisa
    Castaman, Giancarlo
    Pochopien, Michal
    Aballea, Samuel
    Drzewiecka, Aleksandra
    Hakimi, Zalmai
    Nazir, Jameel
    Fatoye, Francis
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1068 - 1075
  • [38] A Retrospective Observational Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US
    Cockerham, Alex
    Wilson, Amanda
    Frick, Andrew
    Dasmahapatra, Pronabesh
    [J]. BLOOD, 2021, 138
  • [39] Plasma-derived versus recombinant factor VIII for the treatment of hemophilia A
    Kasper, CK
    [J]. VOX SANGUINIS, 1996, 70 : 17 - 20
  • [40] Cell-mediated immune response to recombinant factor VIII-Fc in hemophilia A mice
    Krishnamoorthy, S.
    Valee, S.
    Liu, T.
    Drager, D.
    Light, D.
    Pierce, G.
    Jiang, H.
    [J]. HAEMOPHILIA, 2012, 18 : 91 - 91
12345